Skip to main content

KILL Aditxt Subsidiary Adimune Announces Positive Results from Mayo Clinic Pre-Clinical Studies to Support FDA and European Regulatory Submissions for Type 1 Diabetes, Psoriasis, and Stiff Person Syndrome Human Trials

 

Aditxt, Inc. requests that their press release NewsItemId: 20250414955183 issued April 14, 2025 “Aditxt Subsidiary Adimune Announces Positive Results from Mayo Clinic Pre-Clinical Studies to Support FDA and European Regulatory Submissions for Type 1 Diabetes, Psoriasis, and Stiff Person Syndrome Human Trials” be killed.

The release was issued in error by Aditxt, Inc.

A replacement release will not be issued at this time.

Contacts

Aditxt, Inc. 

Corporate Communications 

Jeff Ramson, PCG Advisory, Inc. 

T: 646-863-6893 

contactus@aditxt.com

Recent Quotes

View More
Symbol Price Change (%)
AMZN  204.12
-5.99 (-2.85%)
AAPL  268.01
+3.44 (1.30%)
AMD  195.16
-4.99 (-2.49%)
BAC  51.29
-1.77 (-3.34%)
GOOG  313.00
-1.90 (-0.60%)
META  640.39
-15.27 (-2.33%)
MSFT  386.53
-10.70 (-2.69%)
NVDA  190.98
+1.16 (0.61%)
ORCL  139.90
-8.18 (-5.52%)
TSLA  394.70
-17.12 (-4.16%)
Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the Privacy Policy and Terms Of Service.